Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients

Pediatr Blood Cancer. 2011 Aug;57(2):191-8. doi: 10.1002/pbc.23114. Epub 2011 Apr 4.


This guideline provides clinicians caring for children with an approach to assessing the acute emetogenic potential of antineoplastic therapies. It was developed by an international, inter-professional panel of clinicians and researchers using AGREE and CAN-ADAPTE methods. The emetogenicity of antineoplastic agents was evaluated and ranked as high, moderate, low, or minimal. The emetogenicity of multiple-agent and multiple-day antineoplastic therapy was also classified. Gaps in the evidence used to underpin the guideline recommendations were identified. The contribution of this guideline to the prevention of antineoplastic-induced nausea and vomiting in individual children about to receive antineoplastic therapy requires prospective evaluation.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / classification*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / classification
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Neoplasms / drug therapy*
  • Risk Assessment
  • Vomiting / chemically induced
  • Vomiting / prevention & control*


  • Antineoplastic Agents